SG10201706206PA - Pyridone amides as modulators of sodium channels - Google Patents
Pyridone amides as modulators of sodium channelsInfo
- Publication number
- SG10201706206PA SG10201706206PA SG10201706206PA SG10201706206PA SG10201706206PA SG 10201706206P A SG10201706206P A SG 10201706206PA SG 10201706206P A SG10201706206P A SG 10201706206PA SG 10201706206P A SG10201706206P A SG 10201706206PA SG 10201706206P A SG10201706206P A SG 10201706206PA
- Authority
- SG
- Singapore
- Prior art keywords
- modulators
- sodium channels
- pyridone amides
- pyridone
- amides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
- C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361759059P | 2013-01-31 | 2013-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201706206PA true SG10201706206PA (en) | 2017-08-30 |
Family
ID=50073531
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201505953TA SG11201505953TA (en) | 2013-01-31 | 2014-01-29 | Pyridone amides as modulators of sodium channels |
SG10201706206PA SG10201706206PA (en) | 2013-01-31 | 2014-01-29 | Pyridone amides as modulators of sodium channels |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201505953TA SG11201505953TA (en) | 2013-01-31 | 2014-01-29 | Pyridone amides as modulators of sodium channels |
Country Status (34)
Country | Link |
---|---|
US (6) | US9051270B2 (en) |
EP (3) | EP3239134B1 (en) |
JP (4) | JP6389194B2 (en) |
KR (2) | KR102295748B1 (en) |
CN (2) | CN105026373B (en) |
AP (1) | AP2015008633A0 (en) |
AR (1) | AR094667A1 (en) |
AU (3) | AU2014212509B2 (en) |
BR (1) | BR112015018289A2 (en) |
CA (1) | CA2898866C (en) |
CL (1) | CL2015002147A1 (en) |
CY (1) | CY1119163T1 (en) |
DK (2) | DK3239134T3 (en) |
ES (2) | ES2626555T3 (en) |
GE (2) | GEP20217286B (en) |
HK (2) | HK1217693A1 (en) |
HR (2) | HRP20170787T1 (en) |
HU (2) | HUE033370T2 (en) |
IL (1) | IL240195B (en) |
LT (2) | LT3239134T (en) |
MX (2) | MX2021003687A (en) |
NZ (2) | NZ750187A (en) |
PE (2) | PE20191495A1 (en) |
PH (1) | PH12015501661A1 (en) |
PL (2) | PL2953931T3 (en) |
PT (2) | PT2953931T (en) |
RS (2) | RS61503B1 (en) |
RU (1) | RU2662223C2 (en) |
SG (2) | SG11201505953TA (en) |
SI (2) | SI2953931T1 (en) |
TW (2) | TWI655187B (en) |
UA (1) | UA120589C2 (en) |
UY (1) | UY35288A (en) |
WO (1) | WO2014120808A1 (en) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2773641B1 (en) | 2011-10-31 | 2017-09-27 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
WO2013064983A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
SG11201408284VA (en) | 2012-05-22 | 2015-02-27 | Xenon Pharmaceuticals Inc | N-substituted benzamides and their use in the treatment of pain |
EP2870138B1 (en) | 2012-07-06 | 2018-08-22 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
EP2951168B1 (en) | 2013-01-31 | 2017-01-04 | Vertex Pharmaceuticals Incorporated | Quinoline and quinoxaline amides as modulators of sodium channels |
EP3239134B1 (en) * | 2013-01-31 | 2020-12-23 | Vertex Pharmaceuticals Incorporated | Pyridone amides as modulators of sodium channels |
CN105263490B (en) | 2013-03-14 | 2018-05-22 | 基因泰克公司 | Substituted Triazolopyridine and its application method |
JP6227112B2 (en) | 2013-03-15 | 2017-11-08 | ジェネンテック, インコーポレイテッド | Substituted benzoxazole and methods of use |
CN105683157B (en) | 2013-07-19 | 2019-07-19 | 沃泰克斯药物股份有限公司 | Sulfonamides as sodium channel modulators |
CA2931732A1 (en) | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
RU2692766C1 (en) | 2013-12-13 | 2019-06-27 | Вертекс Фармасьютикалз Инкорпорейтед | Prodrugs of pyridonamides used as modulators of sodium channels |
CN106715418A (en) | 2014-07-07 | 2017-05-24 | 基因泰克公司 | Therapeutic compounds and methods of use thereof |
MA42118A (en) | 2015-05-22 | 2018-03-28 | Genentech Inc | BENZAMIDES SUBSTITUTED AND THEIR METHODS OF USE |
JP2018526371A (en) | 2015-08-27 | 2018-09-13 | ジェネンテック, インコーポレイテッド | Therapeutic compounds and methods of use thereof |
KR20180067561A (en) | 2015-09-28 | 2018-06-20 | 제넨테크, 인크. | Therapeutic compounds and methods for their use |
EP3380466A1 (en) | 2015-11-25 | 2018-10-03 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
MX2018009870A (en) | 2016-02-15 | 2018-11-29 | Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh | Taf1 inhibitors for the therapy of cancer. |
US20170239183A1 (en) * | 2016-02-23 | 2017-08-24 | PixarBio Corporation | COMPOSITIONS COMPRISING NAv1.7 SELECTIVE INHIBITORS FOR TREATING ACUTE, POST-OPERATIVE, OR CHRONIC PAIN AND METHODS OF USING THE SAME |
EP3436432B1 (en) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
EP3526205A4 (en) | 2016-10-17 | 2020-05-27 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
US10793550B2 (en) | 2017-03-24 | 2020-10-06 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
IL270680B (en) | 2017-05-16 | 2022-06-01 | Vertex Pharma | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
SG11202000230VA (en) | 2017-07-11 | 2020-02-27 | Vertex Pharma | Carboxamides as modulators of sodium channels |
TW202002971A (en) | 2018-02-12 | 2020-01-16 | 美商維泰克斯製藥公司 | A method of treating pain |
JP2021514980A (en) | 2018-02-26 | 2021-06-17 | ジェネンテック, インコーポレイテッド | Pyridine-sulfonamide compounds and their use for pain and related pathologies |
WO2019191702A1 (en) | 2018-03-30 | 2019-10-03 | F. Hoffmann-La Roche Ag | Substituted hydro-pyrido-azines as sodium channel inhibitors |
EP3873893A1 (en) | 2018-11-02 | 2021-09-08 | Merck Sharp & Dohme Corp. | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
US20220073471A1 (en) * | 2019-01-04 | 2022-03-10 | Jiangsu Hengrui Medicine Co., Ltd. | 6-oxo-1,6-dihydropyridazine derivative, preparation method therefor and medical use thereof |
US20220110923A1 (en) | 2019-01-10 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
TW202043200A (en) * | 2019-01-25 | 2020-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 2-oxo-1,2-dihydropyridin derivative, a preparation method thereof and a medical use thereof |
MX2021009539A (en) * | 2019-02-20 | 2021-11-04 | Jiangsu Hengrui Medicine Co | 6-oxo-1,6-dihydropyridazine prodrug derivative, preparation method therefor, and application thereof in medicine. |
WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
WO2021018165A1 (en) * | 2019-07-30 | 2021-02-04 | 江苏恒瑞医药股份有限公司 | Pyridine benzamide derivative, preparation method for same, and medicinal applications thereof |
CN112390745B (en) * | 2019-08-19 | 2022-10-21 | 江苏恒瑞医药股份有限公司 | Pyridine nicotinamide derivatives, preparation method and medical application thereof |
TW202115038A (en) * | 2019-08-19 | 2021-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Benzamide fused aromatic ring derivatives, preparation process and medical use thereof |
JP2022548104A (en) * | 2019-09-12 | 2022-11-16 | オリオン コーポレーション | Pyridine nitrogen oxide and its production method and use |
MX2022006865A (en) | 2019-12-06 | 2022-07-11 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels. |
CN113045487A (en) * | 2019-12-27 | 2021-06-29 | 明慧医药(上海)有限公司 | Selective sodium channel regulator and preparation and application thereof |
CN114437062A (en) * | 2020-04-30 | 2022-05-06 | 成都海博为药业有限公司 | Compound capable of being used as sodium channel regulator and application thereof |
IL299180A (en) | 2020-06-17 | 2023-02-01 | Merck Sharp & Dohme Llc | 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors |
CN113880771B (en) * | 2020-07-03 | 2023-09-19 | 福建盛迪医药有限公司 | Selective Na v Crystalline forms of inhibitors and methods of making the same |
CN111808019B (en) * | 2020-09-08 | 2020-11-27 | 上海济煜医药科技有限公司 | Fused ring compound and application thereof |
CN114031518B (en) | 2020-12-08 | 2023-08-18 | 成都海博为药业有限公司 | Benzylamine or benzyl alcohol derivative and application thereof |
US20220380338A1 (en) | 2021-05-07 | 2022-12-01 | Merck Sharp & Dohme Llc | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
CA3221788A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
TW202313593A (en) | 2021-06-04 | 2023-04-01 | 美商維泰克斯製藥公司 | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
AU2022286511A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
EP4347583A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
AU2022284952A1 (en) | 2021-06-04 | 2023-12-14 | Vertex Pharmaceuticals Incorporated | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
CA3221939A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
AR126670A1 (en) | 2021-08-02 | 2023-11-01 | Eurofarma Laboratorios S A | N-ACYLYDRAZONIC COMPOUNDS INHIBITORS OF Nav 1.7 AND/OR Nav 1.8, THEIR OBTAINING PROCESSES, COMPOSITIONS, USES, TREATMENT METHODS OF THESE AND KITS |
AR126669A1 (en) | 2021-08-02 | 2023-11-01 | Eurofarma Laboratorios S A | N-ACYLYDRAZONIC COMPOUNDS INHIBITORS OF Nav 1.7 AND/OR Nav 1.8, THEIR OBTAINING PROCESSES, COMPOSITIONS, USES, TREATMENT METHODS OF THESE AND KITS |
CN116655497A (en) * | 2022-02-25 | 2023-08-29 | 中国科学院上海药物研究所 | Amidine derivative compound and preparation method and application thereof |
WO2023205465A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
US20230373925A1 (en) | 2022-04-22 | 2023-11-23 | Vertex Pharma | Heteroaryl compounds for the treatment of pain |
WO2023205778A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023207949A1 (en) * | 2022-04-25 | 2023-11-02 | 中国科学院上海药物研究所 | Fused ring compound and use thereof |
WO2023211990A1 (en) | 2022-04-25 | 2023-11-02 | Siteone Therapeutics, Inc. | Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH598252A5 (en) | 1974-01-04 | 1978-04-28 | Hoffmann La Roche | |
GB1447583A (en) * | 1974-02-04 | 1976-08-25 | Ici Ltd | Xanthene derivatives |
US4086350A (en) * | 1974-11-06 | 1978-04-25 | Smithkline Corporation | Pharmaceutical compositions and method of producing anti-psychotic activity without extrapyramidal symptoms |
GB1543964A (en) * | 1976-04-08 | 1979-04-11 | Ici Ltd | Method of antagonising herbicides on soyabean and cotton |
US5281620A (en) * | 1986-12-23 | 1994-01-25 | Cancer Research Campaign Technology Limited | Compounds having antitumor and antibacterial properties |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
JP3285391B2 (en) * | 1992-09-01 | 2002-05-27 | 日本化学工業株式会社 | Method for producing 2-phenoxybenzoic acid |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
WO2001021652A1 (en) | 1999-09-24 | 2001-03-29 | The Johns Hopkins University School Of Medicine | Methods for identifying an agent that corrects defective protein folding |
JP2003034671A (en) * | 2001-05-17 | 2003-02-07 | Nippon Nohyaku Co Ltd | Benzamide derivatives and agricultural chemicals as well as use thereof |
PL218749B1 (en) * | 2002-02-14 | 2015-01-30 | Pharmacia Corp | Substituted pyridinones as modulators of p38 map kinase |
JP2007501804A (en) * | 2003-08-08 | 2007-02-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | Compositions useful as inhibitors of voltage-gated sodium channels |
CA2536870C (en) * | 2003-09-03 | 2009-10-27 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
KR20070026845A (en) | 2004-07-23 | 2007-03-08 | 화이자 인코포레이티드 | Pyridine derivatives |
NZ564374A (en) | 2005-06-09 | 2010-11-26 | Vertex Pharma | Indane derivatives as modulators of ion channels |
EP1928871A2 (en) | 2005-09-09 | 2008-06-11 | Vertex Pharmaceuticals, Inc. | Bicyclic derivatives as modulators of voltage gated ion channels |
AU2006304283B2 (en) | 2005-10-12 | 2012-01-19 | Vertex Pharmaceuticals Incorporated | Biphenyl derivatives as modulators of voltage gated ion channels |
WO2007120647A2 (en) * | 2006-04-11 | 2007-10-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of voltage-gated sodium channels |
CA2684105C (en) | 2007-05-03 | 2011-09-06 | Pfizer Limited | Pyridine derivatives |
CA2687764A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
US8779197B2 (en) * | 2007-10-11 | 2014-07-15 | Vertex Pharmaceuticals Incorporated | Aryl amides useful as inhibitors of voltage-gated sodium channels |
NZ584475A (en) | 2007-10-11 | 2012-07-27 | Vertex Pharma | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
KR20100066583A (en) | 2007-10-11 | 2010-06-17 | 버텍스 파마슈티칼스 인코포레이티드 | Amides useful as inhibitors of voltage-gated sodium channels |
ES2553412T3 (en) * | 2007-10-31 | 2015-12-09 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for pain management |
CA2745952A1 (en) * | 2008-12-23 | 2010-07-01 | F.Hoffmann-La Roche Ag | Dihydropyridone amides as p2x7 modulators |
JP5685203B2 (en) * | 2009-05-29 | 2015-03-18 | ラクオリア創薬株式会社 | Aryl-substituted carboxamide derivatives as calcium channel blockers or sodium channel blockers |
TW201103904A (en) * | 2009-06-11 | 2011-02-01 | Hoffmann La Roche | Janus kinase inhibitor compounds and methods |
JP2013522305A (en) | 2010-03-15 | 2013-06-13 | アムジエン・インコーポレーテツド | Spiro-tetracyclic ring compounds as β-secretase regulators |
WO2011140425A1 (en) | 2010-05-06 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
WO2012050918A2 (en) | 2010-09-29 | 2012-04-19 | Presidio Pharmaceutical, Inc. | Tricyclic fused ring inhibitors of hepatitis c |
SG192248A1 (en) | 2011-02-02 | 2013-09-30 | Vertex Pharma | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels |
EP2675810A1 (en) | 2011-02-15 | 2013-12-25 | Amgen Inc. | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use |
CN103443105A (en) | 2011-02-18 | 2013-12-11 | 沃泰克斯药物股份有限公司 | Chroman-spirocyclic piperidine amides as modulators of ion channels |
CA2829803A1 (en) | 2011-03-14 | 2012-09-20 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
WO2012122716A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases |
KR101844623B1 (en) | 2011-03-29 | 2018-04-02 | 사노피 | Otamixaban formulations with improved stability |
JP5730398B2 (en) | 2011-08-10 | 2015-06-10 | 三菱電機株式会社 | Induction heating cooker and its program |
CN102584774B (en) | 2011-12-22 | 2014-08-06 | 合肥工业大学 | Xanthenone derivative and application thereof |
EP2822953B9 (en) | 2012-03-06 | 2017-06-21 | Pfizer Inc | Macrocyclic derivatives for the treatment of proliferative diseases |
CN102659628B (en) | 2012-04-26 | 2014-07-02 | 四川大学 | Phthalonitrile monomer containing aromatic polyamide, synthetizing method thereof and poly phthalonitrile resin produced through solidification of phthalonitrile monomer |
EP2951168B1 (en) | 2013-01-31 | 2017-01-04 | Vertex Pharmaceuticals Incorporated | Quinoline and quinoxaline amides as modulators of sodium channels |
TWI606048B (en) | 2013-01-31 | 2017-11-21 | 帝人製藥股份有限公司 | Azolebenzene derivatives |
EP3239134B1 (en) | 2013-01-31 | 2020-12-23 | Vertex Pharmaceuticals Incorporated | Pyridone amides as modulators of sodium channels |
KR102226588B1 (en) | 2013-01-31 | 2021-03-11 | 버텍스 파마슈티칼스 인코포레이티드 | Amides as modulators of sodium channels |
CN105683157B (en) | 2013-07-19 | 2019-07-19 | 沃泰克斯药物股份有限公司 | Sulfonamides as sodium channel modulators |
RU2692766C1 (en) | 2013-12-13 | 2019-06-27 | Вертекс Фармасьютикалз Инкорпорейтед | Prodrugs of pyridonamides used as modulators of sodium channels |
SG11202000230VA (en) | 2017-07-11 | 2020-02-27 | Vertex Pharma | Carboxamides as modulators of sodium channels |
TW202002971A (en) | 2018-02-12 | 2020-01-16 | 美商維泰克斯製藥公司 | A method of treating pain |
-
2014
- 2014-01-29 EP EP17152492.9A patent/EP3239134B1/en active Active
- 2014-01-29 KR KR1020217007028A patent/KR102295748B1/en active IP Right Grant
- 2014-01-29 GE GEAP201413922A patent/GEP20217286B/en unknown
- 2014-01-29 AP AP2015008633A patent/AP2015008633A0/en unknown
- 2014-01-29 RS RS20210235A patent/RS61503B1/en unknown
- 2014-01-29 ES ES14704053T patent/ES2626555T3/en active Active
- 2014-01-29 DK DK17152492.9T patent/DK3239134T3/en active
- 2014-01-29 HU HUE14704053A patent/HUE033370T2/en unknown
- 2014-01-29 TW TW103103691A patent/TWI655187B/en active
- 2014-01-29 PL PL14704053T patent/PL2953931T3/en unknown
- 2014-01-29 SI SI201430220T patent/SI2953931T1/en unknown
- 2014-01-29 MX MX2021003687A patent/MX2021003687A/en unknown
- 2014-01-29 JP JP2015556109A patent/JP6389194B2/en active Active
- 2014-01-29 DK DK14704053.9T patent/DK2953931T3/en active
- 2014-01-29 PE PE2019001687A patent/PE20191495A1/en unknown
- 2014-01-29 PT PT147040539T patent/PT2953931T/en unknown
- 2014-01-29 WO PCT/US2014/013652 patent/WO2014120808A1/en active Application Filing
- 2014-01-29 CN CN201480011392.XA patent/CN105026373B/en active Active
- 2014-01-29 CA CA2898866A patent/CA2898866C/en active Active
- 2014-01-29 TW TW108105717A patent/TWI714967B/en active
- 2014-01-29 LT LTEP17152492.9T patent/LT3239134T/en unknown
- 2014-01-29 UY UY0001035288A patent/UY35288A/en active IP Right Grant
- 2014-01-29 SG SG11201505953TA patent/SG11201505953TA/en unknown
- 2014-01-29 UA UAA201508443A patent/UA120589C2/en unknown
- 2014-01-29 SG SG10201706206PA patent/SG10201706206PA/en unknown
- 2014-01-29 CN CN201810153601.4A patent/CN108164457B/en active Active
- 2014-01-29 NZ NZ750187A patent/NZ750187A/en unknown
- 2014-01-29 AU AU2014212509A patent/AU2014212509B2/en active Active
- 2014-01-29 NZ NZ710270A patent/NZ710270A/en unknown
- 2014-01-29 PE PE2015001572A patent/PE20151781A1/en active IP Right Grant
- 2014-01-29 MX MX2015009602A patent/MX2015009602A/en unknown
- 2014-01-29 LT LTEP14704053.9T patent/LT2953931T/en unknown
- 2014-01-29 KR KR1020157023601A patent/KR102227592B1/en active IP Right Grant
- 2014-01-29 EP EP14704053.9A patent/EP2953931B1/en active Active
- 2014-01-29 BR BR112015018289A patent/BR112015018289A2/en not_active Application Discontinuation
- 2014-01-29 RS RS20170516A patent/RS56015B1/en unknown
- 2014-01-29 RU RU2015136795A patent/RU2662223C2/en active
- 2014-01-29 GE GEAP201414909A patent/GEP20207177B/en unknown
- 2014-01-29 HU HUE17152492A patent/HUE053448T2/en unknown
- 2014-01-29 ES ES17152492T patent/ES2857687T3/en active Active
- 2014-01-29 PL PL17152492T patent/PL3239134T3/en unknown
- 2014-01-29 PT PT171524929T patent/PT3239134T/en unknown
- 2014-01-29 AR ARP140100281A patent/AR094667A1/en active IP Right Grant
- 2014-01-29 SI SI201431756T patent/SI3239134T1/en unknown
- 2014-01-29 US US14/167,759 patent/US9051270B2/en active Active
- 2014-01-29 EP EP20216557.7A patent/EP3865475A1/en active Pending
-
2015
- 2015-04-29 US US14/699,437 patent/US9393235B2/en active Active
- 2015-07-27 PH PH12015501661A patent/PH12015501661A1/en unknown
- 2015-07-28 IL IL24019515A patent/IL240195B/en active IP Right Grant
- 2015-07-31 CL CL2015002147A patent/CL2015002147A1/en unknown
-
2016
- 2016-05-13 HK HK16105503.1A patent/HK1217693A1/en unknown
- 2016-06-06 US US15/174,896 patent/US9758483B2/en active Active
-
2017
- 2017-05-26 HR HRP20170787TT patent/HRP20170787T1/en unknown
- 2017-05-31 CY CY20171100560T patent/CY1119163T1/en unknown
- 2017-08-03 US US15/667,722 patent/US10087143B2/en active Active
-
2018
- 2018-02-20 JP JP2018027902A patent/JP6741704B2/en active Active
- 2018-03-15 HK HK18103628.4A patent/HK1244269A1/en unknown
- 2018-08-09 AU AU2018214105A patent/AU2018214105B9/en active Active
- 2018-08-21 US US16/107,109 patent/US10738009B2/en active Active
-
2019
- 2019-03-25 JP JP2019056505A patent/JP2019089861A/en not_active Withdrawn
-
2020
- 2020-06-24 US US16/910,965 patent/US11673864B2/en active Active
- 2020-07-02 AU AU2020204425A patent/AU2020204425A1/en not_active Abandoned
- 2020-10-07 JP JP2020169731A patent/JP2021001232A/en active Pending
-
2021
- 2021-03-01 HR HRP20210349TT patent/HRP20210349T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1244269A1 (en) | Pyridone amides as modulators of sodium channels | |
HRP20181563T1 (en) | Prodrugs of pyridone amides useful as modulators of sodium channels | |
HK1217692A1 (en) | Amides as modulators of sodium channels | |
HK1223604A1 (en) | Sulfonamides as modulators of sodium channels | |
HRP20182004T1 (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
HK1217691A1 (en) | Quinoline and quinazoline amides as modulators of sodium channels | |
HK1223611A1 (en) | Fused piperidine amides as modulators of ion channels |